Film Coated Tablet
Ranitidine 150 mg
Tablet RANIMIL-150 is a gastric secretion inhibitor containing Ranitidine 150 mg per tablet as Ranitidine hydrochloride USP. It is a histamine H2-receptor antagonist and is effective in conditions where inhibition of gastric acid secretions is beneficial, such as duodenal and gastric ulcers. Ranitidine is readily absorbed from the gastro-intestinal tract. The peak plasma concentration reaches in about 2 hours after oral administration. After oral administration, The bioavailability is about 50% and elimination half life from plasma is around 2 to 3 hours. About 15% of the oral dose is weakly bound to plasma protein. A small portion (about 4%) of the dose is metabolised in the liver, and about 30% is excreted unchanged in the urine in 24 hours.
Ranimil-150 is indicated in duodenal and gastric ulcers, oesophageal reflux, dyspepsia, zollinger-Eillison syndrome. It is also useful for the prophylaxis of gastrointestinal hemorrhage as a consequence of stress ulceration.
Dosage and Administration:
In duodenal and gastric ulcer 1 tablet twice daily for four weeks. Continued maintenance treatment 1 tablet at bed time is recommended for patients with a history of recurrents ulceration. In refluxoesophagitis 1 tablet three times daily and this may be increased as necessary up to 6 tablets.
Headache, dizziness, skin rash, occasional reversible amenorrhoea and nausea may be found.
Patients with known hypersensitivity to ranitidine should not be given RANIMIL-150.
RANIMIL-150 Should be given in reduced dosage to patients with impaired renal function.
RANIMIL-150 should be given with care during pregnancy and lactation if it is strictly necessary. When gastric ulcer is suspected the possibility of malignancy should be excluded before therapy. Patients receiving prolonged treatment should be examined periodically.
10 strips of 10 tablets in alu-alu blister pack in a paper box.
Each of the film coated tablet contains Ranitidine hydrochloride USP equivalent to 150 mg of Ranitidine base.